As revealed in Fig. 2B and Table 2, ANKRD22 extensively increased in PAAD, leading to a higher risk of PC patients about the survival time, HR = 1.7 and p = 0.0082. Here, ANKRD22 is linked to pancreatic adenocarcinoma.